1-butoxy-3-ethylbenzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-butoxy-3-ethylbenzene
• 英文别名: 3-Ethylphenol, n-butyl ether
• 化学式: C₁₂H₁₈O
• 分子量: 178.274
• InChiKey: PYXKHJBRRJAYDJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-溴-3-乙基苯 、 正丁醇 在 三正丁胺 1-(2-di-tert-butylphosphino-3,4,5,6-tetramethylphenyl)-2-iso-propylnaphthalene 、 palladium diacetate 、 caesium carbonate 作用下， 反应 18.0h， 以91%的产率得到1-butoxy-3-ethylbenzene
  参考文献：
  名称：

  使用可调配体允许分子间 Pd 催化的 C-O 键形成

  摘要：

  庞大的联芳基膦配体通过促进还原消除以消除 β-氢化物为代价，促进了 Pd 催化的芳基卤化物与伯醇和仲醇的 CO 偶联反应。它们成功的关键是能够将配体的大小与底物组合的大小相匹配。实现了许多未活化的芳基氯化物和溴化物与环状和非环状仲醇的有效偶联。这包括首次在 Pd 催化的偶联过程中偶联烯丙醇。

  DOI：

  10.1021/ja050471r

文献信息

• UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS
  申请人：Chao Hannguang J.

  公开号：US20080280905A1

  公开（公告）日：2008-11-13

  The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y 1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y 1 receptor activity.

  本发明提供了新型吡啶基或苯基脲及其类似物，它们是选择性的人类P2Y1受体抑制剂。本发明还提供了各种该类药物组成物和调节P2Y1受体活性以治疗对其反应的疾病的方法。
• Solid-Phase Preparation of [18F]Fluorohaloalkanes
  申请人：Brady Frank

  公开号：US20070202039A1

  公开（公告）日：2007-08-30

  The invention relates to a process for the production of an [ 18 F]fluorohaloalkane which comprises treatment of a solid support-bound precursor of formula (I): SOLID SUPPORT-LINKER-SO 2 —O—(CH 2 ) n X  (I) wherein n is an integer of from 1 to 7 and X is chloro, bromo or iodo; with 18 F − to produce the [ 18 F]fluorohaloalkane of formula (II) 18 F—(CH 2 ) n —X  (II) wherein n and X are as defined for the compound of formula (I), optionally followed by (i) removal of excess 18 F − , for example by ion-exchange chromatography; and/or (ii) removal of organic solvent.

  本发明涉及一种制备[18F]氟卤代烷的方法，包括将式(I)的固相支持前体进行处理：SOLID SUPPORT-LINKER-SO2—O—(CH2)nX  (I)，其中n为1至7的整数，X为氯、溴或碘；使用18F−产生式(II)的[18F]氟卤代烷：18F—( )n—X  (II)，其中n和X如式(I)中所定义，可选择性地进行以下步骤：(i)去除多余的18F−，例如通过离子交换色谱法；和/或(ii)去除有机溶剂。
• ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES
  申请人：RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

  公开号：US20160263083A1

  公开（公告）日：2016-09-15

  The invention provides compounds of formula Ia, Ib and Ic: and salts thereof, wherein variables are as described in the specification, as well as compositions comprising a compound of formula Ia-Ic, methods of making such compounds, and methods of using such compounds, e.g., as inhibitors of bacterial RNA polymerase and as antibacterial agents.

  本发明提供了Ia、Ib和Ic式化合物及其盐，其中变量如规范所述，以及包含Ia-Ic式化合物的组合物、制备这种化合物的方法以及使用这种化合物的方法，例如作为细菌RNA聚合酶的抑制剂和抗菌剂。
• An Efficient Intermolecular Palladium-Catalyzed Synthesis of Aryl Ethers
  作者：Karen E. Torraca、Xiaohua Huang、Cynthia A. Parrish、Stephen L. Buchwald

  DOI：10.1021/ja016863p

  日期：2001.10.31
• Compositions And Methods For Treating Toxoplasmosis, Cryptosporidiosis, And Other Apicomplexan Protozoan Related Diseases
  申请人：VAN VOORHIS Wesley C.

  公开号：US20130018040A1

  公开（公告）日：2013-01-17

  Compositions and methods for the treatment of toxoplasmosis, caused by the infectious eukaryotic parasite Toxoplasma gondii ( T. gondii ) and for the treatment of cryptosporidiosis, caused by the infectious eukaryotic parasites Cryptosporidium parvum ( C. parvum ) and Cryptosporidium hominus ( C. hominus ) are described. In particular, the present disclosure is directed to compositions and methods for inhibiting either T. gondii calcium dependent protein kinases (TgCDPKs) or C. parvum and C. hominus calcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-a]pyrazine inhibitors, of the formula, wherein the variables X, Y, Z, L, R 1 , and R 3 are defined herein.